百濟神州(06160.HK)第二季度GAAP淨利潤達9400萬美元 預計未來18個月內將迎來超過20項研發里程碑事件
格隆匯8月6日丨百濟神州(06160.HK)發佈公吿，2025年第二季度總收入達13億美元，同比增長42%； 百悦澤（澤布替尼）全球收入達9.5億美元，同比增長49%。2025年第二季度，GAAP淨利潤為9,400萬美元，與上年同期虧損相比增加2.15億美元，主要得益於收入增長及經營槓桿改善。
2025年第二季度，GAAP下毛利佔全球產品收入為87.4%，上年同期為85.0%。毛利率同比取得增長，主要因為與產品組合中的其他產品相比，百悦澤在全球銷售中佔比更高。毛利率也受益於百悦澤和百澤安生產效率的提高。經調整後（不含折舊及攤銷），2025年第二季度產品銷售毛利率增至88.1%，而上年同期為85.4%。
百濟神州2025年全年總收入指引為50億美元至53億美元，其中包括收入強勁增長的預期，受益於百悦澤在美國的領先地位以及在歐洲和全球其他重要市場的持續擴張。與2024年相比，由於產品組合的改善和生產效率的提高，毛利率預計將位於80%至90%的中高位區間。
公司預計未來18個月內，在血液腫瘤和實體瘤管線中將迎來超過20項里程碑進展。
“第二季度強勁的表現，進一步鞏固了公司在全球腫瘤治療領域的領先地位，並充分證明了我們實現可持續、長期增長的能力”。百濟神州聯合創始人、董事長兼首席執行官歐雷強先生表示，“我們目標明確，正在不斷朝着使命前進，致力於為全球更多患者帶來突破性藥物。百悦澤作為公司血液腫瘤領域的核心產品，確立了同類最佳BTK抑制劑的標杆地位，獲批適應症最廣泛，並在美國市場繼續保持領先優勢，這得益於其在五個適應症中展現出的優異療效、良好的安全性以及積極的患者獲益。另外兩款處於3期臨牀研究階段的血液腫瘤產品——BCL2抑制劑索托克拉和BTK嵌合式降解啟動化合物(CDAC)BGB-16673——將在近期公佈關鍵性數據並啟動新臨牀試驗，進一步加強我們的領先地位。在近期的投資者研發日活動上，我們展示了清晰的增長路徑，預計未來18個月內將迎來超過20項研發里程碑事件。這也包括在廣泛的實體瘤管線中取得眾多潛在積極進展。我們正針對一系列高發癌症打造全球產品管線”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
